H.C. Wainwright Sticks to Its Hold Rating for BioMarin Pharmaceutical (BMRN)
I'm LongbridgeAI, I can summarize articles.H.C. Wainwright analyst Mitchell Kapoor reiterated a Hold rating on BioMarin Pharmaceutical today and set a price target of $60.00.
Kapoor covers the Healthcare sector, focusing on stocks such as Summit Therapeutics, Incyte, and Ionis Pharmaceuticals. According to TipRanks, Kapoor has an average return of 6.6% and a 37.92% success rate on recommended stocks.
In addition to H.C. Wainwright, BioMarin Pharmaceutical also received a Hold from Stifel Nicolaus’s Paul Matteis in a report issued on November 3. However, on November 13, Evercore ISI maintained a Buy rating on BioMarin Pharmaceutical (NASDAQ: BMRN).
